Cancer immunotherapy and aging: Lessons from the mouse

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer is a disease of the elderly. Since demographic trends indicate that over the next decades the number of elderly people will increase substantially, strategies for cancer prevention and therapy need to be optimized to older patients. Immunotherapy, either through passive or active immunization is a highly targeted type of therapy that is potentially less toxic than chemotherapy or radiation and could, therefore, be especially effective in older, more frail cancer patients. In particular active immunization, i.e., employing patient's own immune system through vaccination, offers great promise since it can potentially keep cancer permanently at bay. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to diminished T-cell responses, a phenomenon also observed in cancer patients per se. To develop cancer vaccines that are effective at older age, the availability of preclinical models that can predict age effects on cancer vaccination is critically important. In this review, current knowledge of diminished T-cell responses in cancer patients and elderly, the results of cancer vaccination in preclinical models and human clinical trials and the impact of aging on immunotherapy will be discussed. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

Original languageEnglish (US)
Title of host publicationHandbook on Immunosenescence: Basic Understanding and Clinical Applications
PublisherSpringer Netherlands
Pages1217-1243
Number of pages27
ISBN (Print)9781402090639, 9781402090622
DOIs
StatePublished - 2009

Fingerprint

Immunotherapy
Vaccination
Neoplasms
Cancer Vaccines
T-Lymphocytes
Active Immunotherapy
Passive Immunization
Poisons
Young Adult
Immune System
Demography
Clinical Trials
Radiation
Drug Therapy
Therapeutics

Keywords

  • Aging
  • Cancer
  • Immunosenescence
  • Immunotherapy
  • Mouse
  • Tumor models
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gravekamp, C. (2009). Cancer immunotherapy and aging: Lessons from the mouse. In Handbook on Immunosenescence: Basic Understanding and Clinical Applications (pp. 1217-1243). Springer Netherlands. https://doi.org/10.1007/978-1-4020-9063-9-59

Cancer immunotherapy and aging : Lessons from the mouse. / Gravekamp, Claudia.

Handbook on Immunosenescence: Basic Understanding and Clinical Applications. Springer Netherlands, 2009. p. 1217-1243.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gravekamp, C 2009, Cancer immunotherapy and aging: Lessons from the mouse. in Handbook on Immunosenescence: Basic Understanding and Clinical Applications. Springer Netherlands, pp. 1217-1243. https://doi.org/10.1007/978-1-4020-9063-9-59
Gravekamp C. Cancer immunotherapy and aging: Lessons from the mouse. In Handbook on Immunosenescence: Basic Understanding and Clinical Applications. Springer Netherlands. 2009. p. 1217-1243 https://doi.org/10.1007/978-1-4020-9063-9-59
Gravekamp, Claudia. / Cancer immunotherapy and aging : Lessons from the mouse. Handbook on Immunosenescence: Basic Understanding and Clinical Applications. Springer Netherlands, 2009. pp. 1217-1243
@inbook{9eabf296114648d4b3edf51d16662558,
title = "Cancer immunotherapy and aging: Lessons from the mouse",
abstract = "Cancer is a disease of the elderly. Since demographic trends indicate that over the next decades the number of elderly people will increase substantially, strategies for cancer prevention and therapy need to be optimized to older patients. Immunotherapy, either through passive or active immunization is a highly targeted type of therapy that is potentially less toxic than chemotherapy or radiation and could, therefore, be especially effective in older, more frail cancer patients. In particular active immunization, i.e., employing patient's own immune system through vaccination, offers great promise since it can potentially keep cancer permanently at bay. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to diminished T-cell responses, a phenomenon also observed in cancer patients per se. To develop cancer vaccines that are effective at older age, the availability of preclinical models that can predict age effects on cancer vaccination is critically important. In this review, current knowledge of diminished T-cell responses in cancer patients and elderly, the results of cancer vaccination in preclinical models and human clinical trials and the impact of aging on immunotherapy will be discussed. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.",
keywords = "Aging, Cancer, Immunosenescence, Immunotherapy, Mouse, Tumor models, Vaccines",
author = "Claudia Gravekamp",
year = "2009",
doi = "10.1007/978-1-4020-9063-9-59",
language = "English (US)",
isbn = "9781402090639",
pages = "1217--1243",
booktitle = "Handbook on Immunosenescence: Basic Understanding and Clinical Applications",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Cancer immunotherapy and aging

T2 - Lessons from the mouse

AU - Gravekamp, Claudia

PY - 2009

Y1 - 2009

N2 - Cancer is a disease of the elderly. Since demographic trends indicate that over the next decades the number of elderly people will increase substantially, strategies for cancer prevention and therapy need to be optimized to older patients. Immunotherapy, either through passive or active immunization is a highly targeted type of therapy that is potentially less toxic than chemotherapy or radiation and could, therefore, be especially effective in older, more frail cancer patients. In particular active immunization, i.e., employing patient's own immune system through vaccination, offers great promise since it can potentially keep cancer permanently at bay. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to diminished T-cell responses, a phenomenon also observed in cancer patients per se. To develop cancer vaccines that are effective at older age, the availability of preclinical models that can predict age effects on cancer vaccination is critically important. In this review, current knowledge of diminished T-cell responses in cancer patients and elderly, the results of cancer vaccination in preclinical models and human clinical trials and the impact of aging on immunotherapy will be discussed. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

AB - Cancer is a disease of the elderly. Since demographic trends indicate that over the next decades the number of elderly people will increase substantially, strategies for cancer prevention and therapy need to be optimized to older patients. Immunotherapy, either through passive or active immunization is a highly targeted type of therapy that is potentially less toxic than chemotherapy or radiation and could, therefore, be especially effective in older, more frail cancer patients. In particular active immunization, i.e., employing patient's own immune system through vaccination, offers great promise since it can potentially keep cancer permanently at bay. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to diminished T-cell responses, a phenomenon also observed in cancer patients per se. To develop cancer vaccines that are effective at older age, the availability of preclinical models that can predict age effects on cancer vaccination is critically important. In this review, current knowledge of diminished T-cell responses in cancer patients and elderly, the results of cancer vaccination in preclinical models and human clinical trials and the impact of aging on immunotherapy will be discussed. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

KW - Aging

KW - Cancer

KW - Immunosenescence

KW - Immunotherapy

KW - Mouse

KW - Tumor models

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84919723311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919723311&partnerID=8YFLogxK

U2 - 10.1007/978-1-4020-9063-9-59

DO - 10.1007/978-1-4020-9063-9-59

M3 - Chapter

AN - SCOPUS:84919723311

SN - 9781402090639

SN - 9781402090622

SP - 1217

EP - 1243

BT - Handbook on Immunosenescence: Basic Understanding and Clinical Applications

PB - Springer Netherlands

ER -